β-galactosylamine | 14196-86-2

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: β-galactosylamine
• 英文别名: D-galactosamine；galactosamine；2-amino-D-2-deoxy-galactose；2-amino-β-D-2-deoxy-galactopyranose；2-amino-2-deoxy-β-D-galactopyranose；2-Amino-2-desoxy-β-D-galactopyranose；beta-D-galactosamine；(2R,3R,4R,5R,6R)-3-amino-6-(hydroxymethyl)oxane-2,4,5-triol
• CAS: 14196-86-2
• 化学式: C₆H₁₃NO₅
• 分子量: 179.173
• InChiKey: MSWZFWKMSRAUBD-VFUOTHLCSA-N

物化性质

• 沸点：
  449.9±45.0 °C(Predicted)
• 密度：
  1.563±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -2.8
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  116
• 氢给体数：
  5
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  β-galactosylamine 在 sodium azide 、 三氟甲磺酸酐 、 碳酸氢铵 、 potassium carbonate 、 copper(II) sulfate 、 1,8-二氮杂双环[5.4.0]十一碳-7-烯 作用下， 以 四氢呋喃 、 甲醇 、 二氯甲烷 、 水 为溶剂， 生成 3,4,6-tri-O-acetyl-2-azido-2-deoxy-α-D-galactopyranosyltrichloroacetimidate
  参考文献：
  名称：

  Synthesis and immunological study of a wall teichoic acid-based vaccine against E. faecium U0317

  摘要：

  A repeat unit of cell wall teichoic acids (WTA) isolated from E. faecium U0317 was chemically synthesized efficiently by a stepwise strategy. It was derivatized with a 5-aminopentanyl linker to facilitate conjugation with carrier proteins KLH and HSA. Immunological studies of the KLH conjugate 1 demonstrated that it could provoke robust immune responses and high titers of IgG antibodies, which could successfully recognize the synthesized WTA repeat unit 3. This result suggested that synthetic glycoconjugate 1 could be a promising vaccine candidate against E. faecium for further studies.

  DOI：

  10.1080/07328303.2017.1390576

文献信息

• PHOSPHORAMIDITE BUILDING BLOCKS FOR SUGAR-CONJUGATED OLIGONUCLEOTIDES
  申请人：AM CHEMICALS LLC

  公开号：US20160083414A1

  公开（公告）日：2016-03-24

  Novel nucleoside phosphoramidite building blocks for preparation of synthetic oligonucleotides containing at least one phosphotriester linkage conjugated to a monosaccharide and synthetic processes for making the same are disclosed. Furthermore, oligomeric compounds are prepared using said building blocks, preferably followed by removal of protecting groups to provide monosaccharide-conjugated oligonucleotides.

  揭示了用于制备含至少一种磷酸三酯键连接的寡核苷酸的合成寡核苷酸的新型核苷酸磷酰胺酯构建模块，其与单糖偶联，并公开了制备这些构建模块的合成过程。此外，使用这些构建模块制备寡聚合物化合物，最好是在去除保护基之后，以提供单糖偶联的寡核苷酸。
• Patentiflorin A Analogs as Antiviral Agents
  申请人：Hong Kong Baptist University

  公开号：US20210060042A1

  公开（公告）日：2021-03-04

  The present disclosure relates to patentiflorin A analogs that are useful as antivirals, such as anti-HIV, anti-coronaviral, anti-Ebola viral, and anti-influenza viral agents and methods of use thereof.

  本公开涉及用作抗病毒药物的帕特尼氟林A类似物，例如抗HIV、抗冠状病毒、抗埃博拉病毒和抗流感病毒药物，以及它们的使用方法。
• CARBOHYDRATE-GLYCOLIPID CONJUGATE VACCINES
  申请人：Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V.

  公开号：US20150238597A1

  公开（公告）日：2015-08-27

  The present invention relates to the field of synthesizing and biologically evaluating of a novel class of carbohydrate-based vaccines. The new vaccines consist of a multi-modular structure which allows applying the vaccine to a whole variety of pathogenes. This method allows preparing vaccines against all pathogens expressing immunogenic carbohydrate antigens. As conjugation of antigenic carbohydrates to proteins is not required the conjugate vaccine is particularly heat stable. No refrigeration is required, a major drawback of protein-based vaccines.

  本发明涉及合成和生物评价一种新型基于碳水化合物的疫苗的领域。这种新疫苗由多模块结构组成，可以将疫苗应用于各种病原体。该方法允许制备针对所有表达免疫原碳水化合物抗原的病原体的疫苗。由于不需要将抗原碳水化合物与蛋白质结合，所以结合疫苗尤其耐热稳定。无需冷藏，这是基于蛋白质的疫苗的一个主要缺点。
• [EN] SUBSTITUTED NAPHTHYRIDINE DERIVATIVES AS INHIBITORS OF MACROPHAGE MIGRATION INHIBITORY FACTOR AND THEIR USE IN THE TREATMENT OF HUMAN DISEASES<br/>[FR] DERIVES DE NAPHTYRIDINE SUBSTITUES SERVANT D'INHIBITEURS DE FACTEUR D'INHIBITION DE LA MIGRATION DES MACROPHAGES ET LEUR UTILISATION POUR TRAITER DES MALADIES HUMAINES
  申请人：AVANIR PHARMACEUTICALS

  公开号：WO2005021546A1

  公开（公告）日：2005-03-10

  Inhibitors of MIF having a naphthyridine backbone are provided which have utility in the treatment of a variety of disorders, including the treatment of pathological conditions associated with MIF activity. The inhibitors of MIF have the following structures: (Ia), (Ib), (Ic), (Id) including stereoisomers, prodrugs and pharmaceutically acceptable salts thereof, wherein n, R, R1, R2, X, Y and Z are as defined herein. Compositions containing an inhibitor of MIF in combination with a pharmaceutically acceptable carrier are also provided, as well as methods for use of the same.

  提供具有萘啶骨架的MIF抑制剂，对多种疾病的治疗具有用处，包括治疗与MIF活性相关的病理状况。MIF的抑制剂具有以下结构：（Ia）、（Ib）、（Ic）、（Id），包括立体异构体、前药和其药用可接受的盐，其中n、R、R1、R2、X、Y和Z如本文所定义。还提供含有MIF抑制剂的组合物，以及其使用方法。
• Inhibitors of macrophage migration inhibitory factor and methods for identifying the same
  申请人：——

  公开号：US20030195194A1

  公开（公告）日：2003-10-16

  Inhibitors of MIF are provided which have utility in the treatment of a variety of disorders, including the treatment of pathological conditions associated with MIF activity. The inhibitors of MIF have the following structures: 1 including stereoisomers, prodrugs and pharmaceutically acceptable salts thereof, wherein n, R 1 , R 2 , R 3 , R 4 , X, Y and Z are as defined herein. Compositions containing an inhibitor of MIF in combination with a pharmaceutically acceptable carrier are also provided, as well as methods for use of the same.

  提供了MIF的抑制剂，对治疗各种疾病具有实用性，包括与MIF活性相关的病理条件的治疗。MIF的抑制剂具有以下结构：包括立体异构体、前药和其药用盐，其中n、R1、R2、R3、R4、X、Y和Z如本文所定义。还提供了含有MIF抑制剂的组合物，与药用载体结合，以及使用方法。